Operating Income (Loss) in USD of Editas Medicine, Inc. from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Editas Medicine, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2014 to Q3 2025.
  • Editas Medicine, Inc. Operating Income (Loss) for the quarter ending September 30, 2025 was -$24.5M, a 62.6% increase year-over-year.
  • Editas Medicine, Inc. Operating Income (Loss) for the twelve months ending September 30, 2025 was -$199M, a 13% increase year-over-year.
  • Editas Medicine, Inc. annual Operating Income (Loss) for 2024 was -$251M, a 48.5% decline from 2023.
  • Editas Medicine, Inc. annual Operating Income (Loss) for 2023 was -$169M, a 25.1% increase from 2022.
  • Editas Medicine, Inc. annual Operating Income (Loss) for 2022 was -$226M, a 17% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)

Editas Medicine, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$199M -$24.5M +$41.1M +62.6% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 -$240M -$51.5M +$20.4M +28.3% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 -$260M -$76.2M -$9.17M -13.7% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-12
Q4 2024 -$251M -$46.6M -$22.6M -94.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-05
Q3 2024 -$229M -$65.7M -$15.5M -30.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 -$213M -$71.9M -$27.8M -63.1% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 -$185M -$67M -$16M -31.5% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-12
Q4 2023 -$169M -$24M +$39.5M +62.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-05
Q3 2023 -$209M -$50.2M +$7.36M +12.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-04
Q2 2023 -$216M -$44.1M +$10.1M +18.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 -$226M -$51M -$211K -0.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 -$226M -$63.4M -$21.8M -52.5% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-05
Q3 2022 -$204M -$57.5M -$18.3M -46.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-03
Q2 2022 -$186M -$54.2M +$1.17M +2.11% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 -$187M -$50.8M +$6.13M +10.8% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q4 2021 -$193M -$41.6M +$24.3M +36.8% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$217M -$39.3M -$48.2M -537% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-02
Q2 2021 -$169M -$55.4M -$24.1M -76.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-03
Q1 2021 -$145M -$56.9M -$10.3M -22% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-04
Q4 2020 -$135M -$65.9M -$26.5M -67.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-22
Q3 2020 -$108M $8.99M +$43.6M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 -$152M -$31.3M +$4.31M +12.1% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$156M -$46.6M -$15.4M -49.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$141M -$39.4M -$13.2M -50.2% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 -$128M -$34.6M -$18.3M -113% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-06
Q2 2019 -$109M -$35.6M +$4.01M +10.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-07
Q1 2019 -$113M -$31.3M +$297K +0.94% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q4 2018 -$114M -$26.3M +$10.2M +28% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-01
Q3 2018 -$124M -$16.3M +$10.5M +39.2% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$134M -$39.7M -$13.5M -51.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 -$121M -$31.6M -$932K -3.04% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q4 2017 -$120M -$36.4M +$2.54M +6.52% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-26
Q3 2017 -$122M -$26.7M -$5.58M -26.4% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 -$117M -$26.1M -$6.92M -36% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$110M -$30.6M -$12.8M -71.7% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-04
Q4 2016 -$97.2M -$39M -$26.6M -215% Oct 1, 2016 Dec 31, 2016 10-K 2019-03-01
Q3 2016 -$70.6M -$21.2M -$13.8M -187% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 -$56.8M -$19.2M -$8.8M -84.7% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 -$48M -$17.8M -$12.7M -246% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q4 2015 -$35.3M -$12.4M Oct 1, 2015 Dec 31, 2015 10-K 2018-03-08
Q3 2015 -$7.38M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 -$10.4M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-10
Q1 2015 -$5.16M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-13

Editas Medicine, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$251M -$82M -48.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-05
2023 -$169M +$56.8M +25.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-05
2022 -$226M -$32.8M -17% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-05
2021 -$193M -$58.3M -43.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-28
2020 -$135M +$6.08M +4.32% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-22
2019 -$141M -$27.2M -23.9% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
2018 -$114M +$6.21M +5.18% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 -$120M -$22.7M -23.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 -$97.2M -$61.9M -175% Jan 1, 2016 Dec 31, 2016 10-K 2019-03-01
2015 -$35.3M -$22.6M -178% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 -$12.7M Jan 1, 2014 Dec 31, 2014 10-K 2017-03-03
* An asterisk sign (*) next to the value indicates that the value is likely invalid.